Your browser doesn't support javascript.
loading
Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
Yu, Zheng-Cheng; Li, Tianhe; Tully, Ellen; Huang, Peng; Chen, Chih-Ning; Oberdoerffer, Philipp; Gaillard, Stephanie; Shih, Ie-Ming; Wang, Tian-Li.
Afiliação
  • Yu ZC; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
  • Li T; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
  • Tully E; Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.
  • Huang P; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
  • Chen CN; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
  • Oberdoerffer P; Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.
  • Gaillard S; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
  • Shih IM; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
  • Wang TL; Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Cancer Res ; 83(16): 2750-2762, 2023 08 15.
Article em En | MEDLINE | ID: mdl-37306706
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article